<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2023.1299977</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular and Infection Microbiology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gut microbiome: decision-makers in the microenvironment of colorectal cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Han</surname>
<given-names>Jingrun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2045645"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Biao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1962303"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Yongnian</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2562112"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yin</surname>
<given-names>Tianyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2004212"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cui</surname>
<given-names>Yuying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Jinming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2551699"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Yanfei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2579333"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Song</surname>
<given-names>Huiyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/583467"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shang</surname>
<given-names>Dong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/477569"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of General Surgery, The First Affiliated Hospital of Dalian Medical University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Departments of Gastrointestinal Surgery, The Second Affiliated Hospital of Dalian Medical University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Institute (College) of Integrative Medicine, Dalian Medical University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Wei Wang, Nanjing Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Zhou Sun, Jilin University, China</p>
<p>Rui Liang, Chongqing University, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Yanfei Yang, <email xlink:href="mailto:13296396007@139.com">13296396007@139.com</email>; Huiyi Song, <email xlink:href="mailto:huiyisongmail@163.com">huiyisongmail@163.com</email>; Dong Shang, <email xlink:href="mailto:shangdong@dmu.edu.cn">shangdong@dmu.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1299977</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>09</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>11</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Han, Zhang, Zhang, Yin, Cui, Liu, Yang, Song and Shang</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Han, Zhang, Zhang, Yin, Cui, Liu, Yang, Song and Shang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Colorectal cancer (CRC) is a common malignancy of the gastrointestinal tract, accounting for the second most common cause of gastrointestinal tumors. As one of the intestinal barriers, gut bacteria form biofilm, participate in intestinal work, and form the living environment of intestinal cells. Metagenomic next-generation sequencing (mNGS) of the gut bacteria in a large number of CRC patients has been established, enabling specific microbial signatures to be associated with colorectal adenomato-carcinoma. Gut bacteria are involved in both benign precursor lesions (polyps), <italic>in situ</italic> growth and metastasis of CRC. Therefore, the term tumorigenic bacteria was proposed in 2018, such as <italic>Escherichia coli</italic>, <italic>Fusobacterium nucleatum</italic>, <italic>enterotoxigenic Bacteroides fragilis</italic>, etc. Meanwhile, bacteria toxins (such as cytolethal distending toxin (CDT), Colibactin (Clb), <italic>B. fragilis</italic> toxin) affect the tumor microenvironment and promote cancer occurrence and tumor immune escape. It is important to note that there are differences in the bacteria of different types of CRC. In this paper, the role of tumorigenic bacteria in the polyp-cancer transformation and the effects of their secreted toxins on the tumor microenvironment will be discussed, thereby further exploring new ideas for the prevention and treatment of CRC.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="fcimb-13-1299977-g004.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>colorectal cancer</kwd>
<kwd>gut bacteria</kwd>
<kwd>tumor microbial microenvironment</kwd>
<kwd>immune escape</kwd>
<kwd>therapy</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="104"/>
<page-count count="11"/>
<word-count count="4521"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Extra-intestinal Microbiome</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Colorectal cancer (CRC) is a malignant tumor of the colon or rectum that usually originates from mucosal epithelial cells. It is a common type of cancer with high incidence rates worldwide. Several risk factors, such as age, family history, dietary habits, intestinal polyps, and inflammatory bowel disease, are associated with the development of CRC (<xref ref-type="bibr" rid="B11">Center et&#xa0;al., 2009</xref>). The intestinal microbiome is a multifaceted ecosystem consisting of a rich array of bacteria, viruses, and fungi. It harbors a vast reservoir of genetic diversity, surpassing that which resides within an individual&#x2019;s own DNA, making it a profoundly intricate and unique entity. The intricate interplay between bacteria and the host leads to multifaceted impacts of intestinal microbiota and their metabolites on the initiation and progression of CRC, as well as the modulation of the immune microenvironment. Intestinal colonizing bacteria secrete metabolites and enter the blood circulation, thereby affecting important physiological processes such as nutrient absorption, material metabolism, and immune defense (<xref ref-type="bibr" rid="B78">Sun et&#xa0;al., 2023</xref>). Moreover, the oncogenic flora promotes the occurrence of CRC by inducing DNA damage in epithelial cells, which in turn promotes the proliferation of bacteria that have a growth advantage in the tumor microenvironment (<xref ref-type="bibr" rid="B81">Tjalsma et&#xa0;al., 2012</xref>; <xref ref-type="bibr" rid="B15">Clavenna et&#xa0;al., 2023</xref>). The definition of intestinal microbiome is becoming more and more clear, and it is related to countless health conditions. These interactions are now understood to occur locally and throughout the body through changes in the immune system and other mechanisms. The local proximity of intestinal microbiome to the colon led many early researchers to study its effect on CRC, making CRC a frontier for studying the response of microbiome to cancer development, progression and treatment.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>The occurrence and development of CRC</title>
<p>CRC originates from the mucosal epithelial cells in the colorectal mucosa layer. Clinically, CRC is mainly secondary to intestinal polyps and inflammatory bowel disease (<xref ref-type="bibr" rid="B20">Dyson and Rutter, 2012</xref>; <xref ref-type="bibr" rid="B89">Wolf et&#xa0;al., 2023</xref>). Novel ideas about CRC progression course are that normal mucosa after mucosal bump, small adenomatous polyp, large adenoma, high-level neoplasia, eventually into malignant tumor. The types of polyp tissue prone to cancer include tubular adenoma, villous adenoma, tubular-villous adenoma (mixed adenoma), and serrated adenoma (<xref ref-type="bibr" rid="B37">Knudsen et&#xa0;al., 2023</xref>). In a recent investigation, researchers delved into the composition of &#x201c;mucosal-associated metabolites&#x201d; in low-grade versus high-grade dysplastic polyps. Notably, they observed an enrichment of the genus <italic>Pelomonas</italic>, a member of the <italic>Proteobacteria phylum</italic>, in the low-grade dysplastic polyps. Conversely, microbiota analyses of high-grade dysplastic adenomas unveiled an elevated presence of the genus <italic>Anaerococcus</italic>, a taxon that has been notably abundant in CRC tissues (<xref ref-type="bibr" rid="B15">Clavenna et&#xa0;al., 2023</xref>). In a clinical study of Chinese patients, it was found that <italic>Bifidobacterium bifidum</italic>, <italic>Candida albicans</italic>, and <italic>Saccharomyces cerevisiae</italic> in the feces of CRC patients were more prevalent than those of healthy population (<xref ref-type="bibr" rid="B46">Li X. et&#xa0;al., 2023</xref>). In research conducted among individuals diagnosed with familial adenomatous polyposis (FAP), the colonic biofilms were observed to harbor oncogenic bacteria, primarily <italic>Escherichia coli</italic> and <italic>Bacteroides fragilis (</italic>
<xref ref-type="bibr" rid="B17">Dejea et&#xa0;al., 2018</xref>).</p>
<p>In approximately 85% of colon cancers, the adenomatous polyposis coli (APC) gene, a critical tumor suppressor, undergoes deletion or inactivation (<xref ref-type="bibr" rid="B28">Grivennikov et&#xa0;al., 2012</xref>). APC gene is not only associated with FAP, but also plays an important role in the occurrence of CRC. NOTUM retains tumor suppressor activity in APC-ineffective adenomas. However, NOTUM becomes a specific oncogene when it develops into adenocarcinoma with p53 deletion (<xref ref-type="bibr" rid="B80">Tian et&#xa0;al., 2023</xref>). Oncogenic microbial communities wield the ability to reshape the entire gut microbiota&#x2019;s composition, inciting pro-inflammatory reactions and incipient cellular metamorphosis, culminating in carcinogenesis (<xref ref-type="bibr" rid="B94">Yan et&#xa0;al., 2023</xref>). Furthermore, oncogenic microbiota catalyze CRC progression through the instigation of DNA damage within the epithelial cells. Epithelial barrier damage may be a consequence of &#x3b2;-catenin activation as well as loss of APC, microbial products drive IL-23/IL-17-mediated tumor growth (<xref ref-type="bibr" rid="B28">Grivennikov et&#xa0;al., 2012</xref>).</p>
<p>As early as 2012, the bacterial driver&#x2013;passenger model was proposed (<xref ref-type="bibr" rid="B81">Tjalsma et&#xa0;al., 2012</xref>). Certain driver bacteria, such as <italic>E. faecalis</italic>, produce extracellular superoxide, which causes cellular DNA damage (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In a 16s RNA sequencing discovery, 7 bacterial genera were identified as potential drivers (e.g., <italic>unclassified Pseudomonadaceae</italic> and <italic>Neissenaceae</italic>) and 12 bacterial genera as potential passengers (e.g., <italic>Staphylococcus</italic> and <italic>Veillonella</italic>) (<xref ref-type="bibr" rid="B27">Geng et&#xa0;al., 2014</xref>). Some studies have also proposed the &#x201c;Alpha-bug&#x201d; model (<xref ref-type="bibr" rid="B72">Sears and Pardoll, 2011</xref>; <xref ref-type="bibr" rid="B7">Avril and DePaolo, 2021</xref>), <italic>enterotoxigenic Bacteroides fragilis</italic> induces colon tumors in mice (<xref ref-type="bibr" rid="B72">Sears and Pardoll, 2011</xref>; <xref ref-type="bibr" rid="B99">Yu and Fang, 2015</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>CRC-associated bacteria.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Strain</th>
<th valign="top" align="left">Pathogenic metabolites</th>
<th valign="top" align="left">Mechanism</th>
<th valign="top" align="left">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<italic>Enterococcus faecalis</italic>
</td>
<td valign="top" align="left">Extracellular Superoxide</td>
<td valign="top" align="left">DNA damage</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B22">Evans et&#xa0;al., 2004</xref>; <xref ref-type="bibr" rid="B81">Tjalsma et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">
<italic>Escherichia coli</italic>
</td>
<td valign="top" align="left">Polyketide synthetase</td>
<td valign="top" align="left">Induces single-strand DNA breaks</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B81">Tjalsma et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">
<italic>Bacill</italic>
<break/>
<italic>us fragilis</italic>
</td>
<td valign="top" align="left">B. fragilis toxin (Metalloproteinase)</td>
<td valign="top" align="left">Promotes T helper 17 cells to increase expression of interleukin-17 (IL-17) to increase tumorigenesis</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B72">Sears and Pardoll, 2011</xref>; <xref ref-type="bibr" rid="B81">Tjalsma et&#xa0;al., 2012</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="left">Increased intestinal barrier permeability</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B72">Sears and Pardoll, 2011</xref>)</td>
</tr>
<tr>
<td valign="top" align="left"/>
<td valign="top" align="left"/>
<td valign="top" align="left">Wnt, NF-&#x3ba;B and Stat3 signal transduction</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B72">Sears and Pardoll, 2011</xref>; <xref ref-type="bibr" rid="B99">Yu and Fang, 2015</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">
<italic>Streptococcus bovis</italic>
</td>
<td valign="top" align="left">
<italic>S.bovis bacterial</italic> wall extracted antigens</td>
<td valign="top" align="left">Inflammation-based sequence of tumor development or dissemination by IL-1, COX-2, and IL-8</td>
<td valign="top" align="left">(<xref ref-type="bibr" rid="B9">Biarc et&#xa0;al., 2004</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3">
<label>3</label>
<title>Gut bacterial products associated with CRC</title>
<p>Bacteria can obtain the ability to penetrate the intestinal mucosal barrier through flagella, pili, and adhesins, as well as adhere to and invade intestinal epithelial cells, produce endotoxin or exotoxin, and then form pathogenicity (<xref ref-type="bibr" rid="B66">Perez-Lopez et&#xa0;al., 2016</xref>). Common pathogenic bacteria have been mentioned before and will not be repeated.</p>
<p>A recent study has suggested that an analysis of the microbial community in tumors holds the potential to identify distinct prognostic subtypes of CRC. This classification system delineates three principal subtypes: OCS1, predominantly associated with <italic>Fusobacteria</italic> and oral pathogens; OCS2, characterized by a prevalence of <italic>Firmicutes</italic> and <italic>Bacteroidetes</italic>; and OCS3, featuring an abundance of <italic>Escherichia</italic>, <italic>Pseudomonas</italic> and <italic>Shigella (</italic>
<xref ref-type="bibr" rid="B60">Mouradov et&#xa0;al., 2023</xref>). OCS1 tumors mostly occur in the right colon and have high pathological grade. In contrast, OCS2 and OCS3 tumors are mostly located in the left colon and rectum with low pathological grade (<xref ref-type="bibr" rid="B60">Mouradov et&#xa0;al., 2023</xref>). There was no significant difference in clinical features between OCS2 and OCS3 (<xref ref-type="bibr" rid="B60">Mouradov et&#xa0;al., 2023</xref>). It has been found that the expression of Gal&#x2010;GalNAc (recognized by Fusobacterium Fap2) may promote the binding of <italic>Fusobacterium</italic> to CRC (<xref ref-type="bibr" rid="B1">Abed et&#xa0;al., 2016</xref>). <italic>F. nucleatum</italic> utilizes the non-lectin structure of Clostridium Fap2 to achieve tumor-promoting effects (<xref ref-type="bibr" rid="B5">Alon-Maimon et&#xa0;al., 2022</xref>). Additionally, in a pathological context, <italic>F. nucleatum</italic> augments its virulence through the secretion of an amyloid-like adhesin called FadA, utilizing a Fap2-like autotransporter (<xref ref-type="bibr" rid="B56">Meng et&#xa0;al., 2021</xref>). In addition, <italic>F. nucleatum</italic> can enhance drug resistance of tumor cells, inhibit neutrophil infiltration, and ultimately change the tumor immune microenvironment (<xref ref-type="bibr" rid="B5">Alon-Maimon et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B26">Garcia-Serrano et&#xa0;al., 2023</xref>). <italic>F. nucleatum</italic> is involved in tumor initiation or progression before cancer formation, which regulating the tumor immune microenvironment and promoting the proliferation of tumor-infiltrating immune cells (<xref ref-type="bibr" rid="B41">Kostic et&#xa0;al., 2013</xref>). <italic>F. nucleatum</italic> pro-inflammatory genes are characterized by upregulation of PTGS2 (<xref ref-type="bibr" rid="B41">Kostic et&#xa0;al., 2013</xref>). Nevertheless, certain experiments have revealed that <italic>F. nucleatum</italic> is not an unequivocal instigator of cancer (<xref ref-type="bibr" rid="B62">Nawab et&#xa0;al., 2023</xref>). Instead, its carcinogenic potential hinges on the particular dietary context in which it operates.</p>
<p>
<italic>E. coli</italic> is involved in the development of CRC through the induction of inflammation and genotoxic host responses by bacteria-derived virulence factors. Some strains of <italic>E. coli</italic> produce a secondary metabolite called colibactin (Clb), and bacteria carrying pks genomic islands have DNA-damaging properties associated with CRC (<xref ref-type="bibr" rid="B19">Dougherty et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B30">Harnack et&#xa0;al., 2023</xref>). Blocking bacterial adhesion attenuates colibactin-mediated genotoxicity and CRC exacerbations (<xref ref-type="bibr" rid="B35">Jans et&#xa0;al., 2023</xref>). Pks+ <italic>E. coli</italic> can opportunistically enter the epithelium and promote existing mucosal damage, while mice colonized with pks+ <italic>E. coli</italic> cannot reestablish functional barriers (<xref ref-type="bibr" rid="B30">Harnack et&#xa0;al., 2023</xref>). Grotesquely, it has also been found that about half of colibactin-producing <italic>E. coli</italic> (CoPEC) can encode cytotoxic necrotizing factor-1 (CNF1) which induces CRC in mice by reducing CoPEC (<xref ref-type="bibr" rid="B13">Chat et&#xa0;al., 2023</xref>). The influence of microorganisms such as <italic>F. nucleatum</italic>, <italic>E. coli</italic>, <italic>enterotoxigenic B. fragilis</italic>, and <italic>Faecalibacterium prausnitzii</italic> on miRNAs is well-established, and this microbial impact leads to the stimulation of tumor growth and exacerbates inflammatory responses (<xref ref-type="bibr" rid="B90">Xing et&#xa0;al., 2022</xref>). Microbiota reprograms mouse intestinal lipid metabolism by suppressing expression of lncRNA Snhg9 in small intestinal epithelial cells (<xref ref-type="bibr" rid="B80">Tian et&#xa0;al., 2023</xref>).</p>
<p>
<italic>Lostridium sporogenes</italic> is responsible for breaking down tryptophan and secreting the metabolite indole propionic acid (IPA), which has been shown to help strengthen the intestinal barrier and interact with the immune system, then change the biological characteristics of the intestine (<xref ref-type="bibr" rid="B18">Dodd et&#xa0;al., 2017</xref>). The gut microbiota metabolizes tryptophan to generate Indole-3-acetic acid (3-IAA), which effectively downregulates the expression of TNF-&#x3b1;. This reduction in TNF-&#x3b1; expression is attributed to the enzymatic conversion of tryptophan, highlighting the microbiota&#x2019;s significant role in modulating inflammatory responses (<xref ref-type="bibr" rid="B82">Tomii et&#xa0;al., 2023</xref>). Furthermore, the metabolization of tryptophan by the bacterial flora results in the production of indole, which exerts regulatory control over mucosal immunity by activating receptors associated with polycyclic aromatic hydrocarbons (<xref ref-type="bibr" rid="B43">Lavelle and Sokol, 2020</xref>; <xref ref-type="bibr" rid="B32">Hezaveh et&#xa0;al., 2022</xref>). <italic>Bacteroides thetaiotaomicron</italic> inhibits tumor growth by producing short-chain fatty acids (SCFAs) such as propionate (<xref ref-type="bibr" rid="B92">Xu et&#xa0;al., 2023</xref>). Elevating the abundance of species such as <italic>Ruminococcaceae</italic>, <italic>Parabacterium</italic>, and <italic>Blautellae</italic> known for their capacity to generate SCFAs, Zearalenone (ZEA) exhibits a notable capacity to effectively suppress the development of colorectal tumors (<xref ref-type="bibr" rid="B44">Leung et&#xa0;al., 2023</xref>). The initiation of AhR signaling is triggered by microbiome-derived formate, which subsequently leads to the expansion of Th17 cells and promotes CRC tumor invasion (<xref ref-type="bibr" rid="B79">Ternes et&#xa0;al., 2022</xref>).</p>
<p>The occurrence and progression of CRC are influenced by DNA mismatch repair (MMR). In a recent examination of DNA mismatch repair deficiencies (dMMR) versus proficient DNA mismatch repair (pMMR), researchers investigated the impact of microbial-driven metabolic reconfiguration (<xref ref-type="bibr" rid="B29">Hale et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B47">Li J. et&#xa0;al., 2023</xref>). In the realm of dMMR, a total of 211 distinct species thrived, with noteworthy representatives including <italic>F. nucleatum</italic>, <italic>A. muciniphila</italic> and <italic>O. splanchnicus (</italic>
<xref ref-type="bibr" rid="B33">Hsueh et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B47">Li J. et&#xa0;al., 2023</xref>). In stark contrast, a mere 2 species displayed a deficiency in dMMR, as exemplified by <italic>F. plautii</italic>. Furthermore, the dMMR environment boasted 13 metabolites in abundance, with retinoic acid being a prominent member, while on the opposite end of the spectrum, 77 metabolites experienced a significant depletion in the dMMR context, encompassing lactic acid, succinic acid, and 2,3-dihydroxyvaleric acid (<xref ref-type="bibr" rid="B47">Li J. et&#xa0;al., 2023</xref>).</p>
<p>The improved prognosis of colon cancer can be attributed to specific mucosal biota, namely <italic>Faecalibacterium prausnitzii</italic> and <italic>Ruminococcus gnavus</italic>. These microorganisms play a pivotal role by producing metabolites that encompass a spectrum of fatty acid species, including medium chain (MCFAs), long-chain (LCFAs), and very long-chain (VLCFAs) fatty acids, alongside ceramides and lysophospholipids (<xref ref-type="bibr" rid="B4">Alexander et&#xa0;al., 2023</xref>).</p>
<p>Similarly, gut bacteria can also produce substances that reverse CRC progression. In a study of female CRC patients, it was found that <italic>Carnobacterium maltaromaticum</italic> was missing (<xref ref-type="bibr" rid="B45">Li Q. et&#xa0;al., 2023</xref>). Intestinal colonization of <italic>C. maltaromaticum</italic> is influenced by estrogen and increases the abundance of vitamin D-related metabolites in colon tissue (<xref ref-type="bibr" rid="B45">Li Q. et&#xa0;al., 2023</xref>). Remarkably, the progression of CRC has been observed to be exacerbated by alterations in the male gut microbiome (<xref ref-type="bibr" rid="B86">Wang L. et&#xa0;al., 2023</xref>). This includes an augmentation in the presence of the pathogenic bacterium <italic>Akkermansia muciniphila</italic> and a reduction in the levels of the beneficial probiotic <italic>Parabacterium kingeri (</italic>
<xref ref-type="bibr" rid="B86">Wang L. et&#xa0;al., 2023</xref>).</p>
</sec>
<sec id="s4">
<label>4</label>
<title>Gut bacteria regulate the tumor microenvironment</title>
<p>The CRC tumor microenvironment (TME) constitutes a multifaceted and intricate ecosystem, and plays a pivotal role in tumor growth, metastasis, and treatment response. TME comprises a diverse array of cellular components and molecular elements. It encompasses tumor cells, immune cell populations, vascular networks, fibroblasts, intestinal flora and the extracellular matrix (ECM) (<xref ref-type="bibr" rid="B101">Zhang et&#xa0;al., 2023</xref>).</p>
<p>It is currently believed that the TME of CRC mainly consists of the intestinal bacteria microenvironment, the inflammatory microenvironment and the hypoxic microenvironment, which work together and coordinate with each other (<xref ref-type="bibr" rid="B87">Wang et&#xa0;al., 2017</xref>). This article mainly describes the impact of intestinal bacteria on TME. <italic>Bifidobacterium adolescentis</italic> is a probiotic found in the human intestine. It can inhibit the proliferation of patholgen in the intestine and maintain the homeostasis of the bacterial microenviroment. It has been experimentally confirmed that <italic>B. adolescentis</italic> inhibits tumorigenesis by inducing a new CD143<sup>+</sup> cancer-associated fibroblasts through Wnt signaling-regulated GAS1 (<xref ref-type="bibr" rid="B14">Chen et&#xa0;al., 2023</xref>). In addition, <italic>B. adolescentis</italic> inhibits colorectal carcinogenesis through TLR2 induction of decorin<sup>+</sup> macrophages (<xref ref-type="bibr" rid="B49">Lin et&#xa0;al., 2023</xref>). In AOM/DSS-induced mice, <italic>B. thetaiotaomicron</italic> suppresses tumorigenesis of colitis-associated CRC and MC38 allograft tumors (<xref ref-type="bibr" rid="B92">Xu et&#xa0;al., 2023</xref>). Not only in CRC, but other experiments have shown that in melanoma, <italic>Eubacterium rectale</italic> significantly improves the efficacy of anti-PD1 treatment and the overall survival rate of tumor-bearing mice (<xref ref-type="bibr" rid="B50">Liu et&#xa0;al., 2023</xref>). <italic>Eubacterium rectale</italic> consumes l-serine to enhance NK cell function and anti-PD1 therapeutic effect, leading to activation of NK cell activity through the FOS/FOSL2 signaling pathway (<xref ref-type="bibr" rid="B50">Liu et&#xa0;al., 2023</xref>).</p>
<p>In an <italic>in vitro</italic> study, <italic>F. nucleatum</italic> infection was found to induce a significant increase in the production of neutrophil extracellular traps (NETs) (<xref ref-type="bibr" rid="B39">Kong et&#xa0;al., 2023</xref>). This demonstrates that <italic>F. nucleatum</italic>-induced NETs indirectly accelerate malignant tumor growth through angiogenesis and promote tumor metastasis. This is exemplified by cellular migration linked to the process of epithelial-mesenchymal transition (EMT), the breakdown of basement membrane proteins facilitated by matrix metalloproteinases (MMPs), and the entrapment of CRC cells (<xref ref-type="bibr" rid="B39">Kong et&#xa0;al., 2023</xref>). In research, exposure of peripheral blood mononuclear cells (PBMCs) to LPS derived from these microorganisms revealed that <italic>F. periodonticum</italic> triggers cytokine synthesis in PBMCs, whereas both <italic>B. fragilis</italic> and <italic>P. asaccharolytica</italic> exerted a suppressive influence (<xref ref-type="bibr" rid="B77">Sulit et&#xa0;al., 2023</xref>). In a study of intratumoral bacteria, elevated autophagy induced by <italic>F. nucleatum</italic> led to increased resistance to reactive oxygen species (ROS) in CRC, this resistance was alleviated, ultimately promoting apoptosis in cancer cells, and apoptosis was triggered by intracellular redox imbalance caused by the interaction with BSA-Cu SAN (<xref ref-type="bibr" rid="B85">Wang X. et&#xa0;al., 2023</xref>).</p>
</sec>
<sec id="s5">
<label>5</label>
<title>Metastasis and immune escape of CRC cells</title>
<p>Studies have shown that relevant DNA analysis of CRC patients and fecal microorganisms found that KRAS gene mutations have a significant impact on distant metastasis of CRC (<xref ref-type="bibr" rid="B76">Sui et&#xa0;al., 2020</xref>). At the same time, in CRC, the abundance of different bacterial groups is also influencing the mutation of KRAS gene, which affects the metastasis and progression of CRC (<xref ref-type="bibr" rid="B76">Sui et&#xa0;al., 2020</xref>). Microorganisms such as <italic>Rosella, Paramecium, Post-Rosella, Staphylococcaceae and Bacillariophyta</italic> in the mutant group significantly affected distant metastasis of CRC through KRAS gene mutation, and their prevalence and metastasis were significantly higher than those in the non-mutant group (<xref ref-type="bibr" rid="B52">Liu et&#xa0;al., 2021</xref>). Furthermore, butyrate, a prominent component among SCFAs, plays a pivotal role in the metabolic processes of normal colorectal epithelial cells (<xref ref-type="bibr" rid="B95">Yan et&#xa0;al., 2024</xref>). Remarkably, a substantial portion of butyrate remains unmetabolized, largely attributed to the fact that colon cells have a Warburg effect pathway (<xref ref-type="bibr" rid="B21">Eslami et&#xa0;al., 2020</xref>). Butyrate serves as a potent histone deacetylase (HDAC) inhibitor, influencing the intricate orchestration of tumor cell metabolism, proliferation, and apoptosis (<xref ref-type="bibr" rid="B40">Korsten et&#xa0;al., 2023</xref>). Consequently, these multifaceted interactions exert a significant impact on the metastatic potential of CRC (<xref ref-type="bibr" rid="B48">Li et&#xa0;al., 2021</xref>). At the same time, it was shown that <italic>F. nucleatum</italic> was found to be highly abundant in CRC and promote CRC metastasis by affecting the miR-1322/CCL20 axis and M2 polarization (<xref ref-type="bibr" rid="B91">Xu et&#xa0;al., 2021</xref>). The ALPK1/NF-&#x3ba;B/ICAM1 pathway can be induced by <italic>F. nucleatum</italic>, leading to enhanced adhesion of CRC cells to intestinal endothelial cells, as well as increased infiltration and distant metastasis (<xref ref-type="bibr" rid="B102">Zhang et&#xa0;al., 2022</xref>). Additionally, EVADR induction has the potential to facilitate CRC metastasis through YBX1-dependent translation processes (<xref ref-type="bibr" rid="B53">Lu et&#xa0;al., 2022</xref>). It has been reported that sustained <italic>F. nucleatum</italic> exposure reduces the diversity of the intestinal microbiota in mice, leading to an imbalance of the intestinal bacteria, and a reorganization of the associated bacteria, which intricately affects colorectal carcinogenesis and progression through the secretion of pro-inflammatory cytokines (<xref ref-type="bibr" rid="B97">Yin et&#xa0;al., 2022</xref>).</p>
<p>
<italic>F. nucleatum p</italic>romotes CRC progression and upregulates PD-L1 protein expression in CRC cell lines, thereby promoting immune escape from the tumor (<xref ref-type="bibr" rid="B25">Gao et&#xa0;al., 2023</xref>). Furthermore, studies have shown that the accumulation of tryptophan derivatives in the gut promotes the formation of suitable targets for immune escape (<xref ref-type="bibr" rid="B67">Puccetti et&#xa0;al., 2015</xref>). Simultaneously, the oncogenic bacteria in the gut, or the metabolites they generate, stimulate the generation of macrophages. The presence of LPS or HCD-induced macrophage infiltration notably triggers the activation of the macrophage-derived CCL5-p65/STAT3-CSN5-PD-L1 signaling pathway, which plays a crucial role in facilitating immune evasion in CRC (<xref ref-type="bibr" rid="B51">Liu et&#xa0;al., 2020</xref>). <italic>F. nucleatum</italic> can also lead to tumor subclones with PD-L1 mutations, nonsense-mediated RNA decay in PD-L1 K1fs, and protein degradation in PD-L162 L1S, thereby promoting its immune escape and tumor metastasis (<xref ref-type="bibr" rid="B75">Stein et&#xa0;al., 2021</xref>). It has also been shown that metabolites associated with <italic>F. nucleatum</italic> can affect up to 50% of dMMR/high microsatellite instability (MSI-H) advanced cancer patients who progress after PD-1 blockade, leading to a high probability of immune escape (<xref ref-type="bibr" rid="B16">Cohen et&#xa0;al., 2020</xref>). <italic>F. nucleatum</italic> has the capacity to promote CRC immune escape by influencing the depletion of human leukocyte antigen class I (HLA-I) (<xref ref-type="bibr" rid="B6">Anderson et&#xa0;al., 2021</xref>). In addition, <italic>F. nucleatum</italic> can also help colon cancer evade immune surveillance and immune elimination by influencing Fas expression (<xref ref-type="bibr" rid="B64">O&#x2019;Connell et&#xa0;al., 2000</xref>). Simultaneously, it can bolster the resistance of CRC to the immune system through the upregulation of FasL expression (<xref ref-type="bibr" rid="B104">Zhu et&#xa0;al., 2005</xref>). In summary, as mentioned in <xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref> CRC immune escape and distant metastasis can be caused by the joint action of intestinal carcinogenic flora and their metabolites.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Immune escape and metastasis of colorectal cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1299977-g001.tif"/>
</fig>
</sec>
<sec id="s6">
<label>6</label>
<title>Microbiological therapy for CRC</title>
<p>The connection between CRC and the gut microbiota is strong. While we still don&#x2019;t fully understand how the microbiota impacts the development and progression of CRC, there is increasing proof that it plays a direct role in influencing signaling pathways, anti-tumor immune responses, and cell growth (<xref ref-type="bibr" rid="B59">Montalban-Arques and Scharl, 2019</xref>). It has been shown that the gut microbiota immune system kills the bacterial flora through specific receptors (Toll-like receptors) and related metabolites (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>). <italic>Clostridium nucleatum, Escherichia coli</italic>, and <italic>Mimicronium fragilis</italic> play a crucial role in the development of CRC. Increasing dietary fiber, including fructans and oligogalactans, has an inhibitory effect on CRC, but it also affects the abundance of Bifidobacteria and Lactobacillus, which increases fecal butyrate concentrations (<xref ref-type="bibr" rid="B68">Rebersek, 2021</xref>). It has been reported that intestinal flora plays an anti-cancer role in the efficacy of PD-L1 immune checkpoint inhibitor blockade (<xref ref-type="bibr" rid="B98">Yu, 2018</xref>). <italic>F. nucleatum</italic> has been shown to induce different immune responses in CRCs with varying microsatellite instability (MSI) states. <italic>F. nucleatum</italic> could induce PD-L8 expression by activating STING signaling during PD-L1 blockade therapy and increase the interferon-gamma (IFN-&#x3b3;) CD1 tumor-infiltrating lymphocytes (TILs), which increases tumor sensitivity to PD-L1 blockade (<xref ref-type="bibr" rid="B24">Gao et&#xa0;al., 2021</xref>). It has also been reported that inhibition of <italic>F. nucleatum</italic> and reduction of its abundance modulate the TLR-4-mediated pathway and MyD88-induced cellular autophagy, which may enhance the chemotherapeutic effect of CRC (<xref ref-type="bibr" rid="B58">Mima et&#xa0;al., 2015</xref>; <xref ref-type="bibr" rid="B100">Yu et&#xa0;al., 2017</xref>). Simultaneously, the restoration of the gut microbiota composition can lead to the augmentation of regulatory T cell populations within the colonic mucosa (<xref ref-type="bibr" rid="B69">Routy et&#xa0;al., 2018</xref>; <xref ref-type="bibr" rid="B74">Shi et&#xa0;al., 2023</xref>). According to recent studies, the anticancer effects of microbial therapies such as bacterial therapies are mainly manifested in the form of bacterial-related biologics, including toxins and peptides (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>). These compounds produce regulatory cytokines, like TNF-&#x3b1;, which leads to the activation or blocking of NF-&#x3ba;B, and they also activate pro-apoptotic proteins (Bcl-1, Bad, Bax, Bak), combine cytochrome C with caspase-9 to form an apoptotic complex, and ultimately promote CRC cells apoptosis. Apoptosis is a key target of cancer therapy and is characterized by an imbalance between cell proliferation and death, resulting in autophagy in CRC cells (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>). Next, how the following related strains and their metabolites combat CRC was explored (<xref ref-type="fig" rid="f3"><bold>Figure 3</bold></xref>). According to some studies, timulation of the inflammatory vesicle pathway triggered by bacteria can activate the immune system, and &#x394;<italic>ppGpp Salmonella typhimurium</italic> inhibits primary and even metastatic CRC by secreting ATP, which causes activation of the NLRP3 inflammatory vesicle in macrophages (<xref ref-type="bibr" rid="B57">Mengesha et&#xa0;al., 2007</xref>; <xref ref-type="bibr" rid="B63">Nguyen et&#xa0;al., 2010</xref>). It has also been shown that the anaerobic strain of <italic>E. coli</italic> counteracts CRC cells by activating the production of T-lymphocytes, thereby greatly contributing to the tumor-protective activity of CD8+ and CD4+ T-cells (<xref ref-type="bibr" rid="B8">Azadi et&#xa0;al., 2021</xref>). At the same time, anaerobic bacterial species can invade and grow in solid tumors, allowing impaired circulation and necrosis of CRC (<xref ref-type="bibr" rid="B23">Fox et&#xa0;al., 1996</xref>; <xref ref-type="bibr" rid="B103">Zhao et&#xa0;al., 2005</xref>; <xref ref-type="bibr" rid="B2">Agrawal et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B36">Kasper et&#xa0;al., 2020</xref>). The antagonistic effect of related toxins on CRC was also investigated. Based on relevant reports and experiments, it has been shown that Clostridium perfringens enterotoxin (CPE) produced by <italic>Clostridium perfringens</italic> can bind to Claudin-3 and -4 receptors on the surface of CRC, leading to the breakdown of cellular osmotic homeostasis and the lysis of cancer cells (<xref ref-type="bibr" rid="B65">Pahle et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B71">Sasaki et&#xa0;al., 2020</xref>). The subunit derived from Gram-positive Corynebacterium diphtheriae can halt protein production by ADP-ribosylating cytoplasmic elongation factor 2 (EF-2), eventually resulting in the demise of CRC cells (<xref ref-type="bibr" rid="B84">Vallera et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B54">Martarelli et&#xa0;al., 2009</xref>). The polycyclic peptide Nisin secreted by <italic>Lactococcus lactis</italic> strains enables the formation of pores in the membranes of Caco-2 and HT-29 CRC cells ultimately leading to membrane depolarization and apoptosis in CRC cells (<xref ref-type="bibr" rid="B3">Ahmadi et&#xa0;al., 2017</xref>). Cytotoxic effects of colistin on CRC cells include membrane pore formation, reduced DNase and RNase activities, and inhibition of murein synthesis (<xref ref-type="bibr" rid="B38">Kohoutova et&#xa0;al., 2020</xref>). Microcin/Microcin E492 causes apoptosis by enabling pore formation in CRC cell membranes and ultimately by binding to Toll-like receptor 4 (<xref ref-type="bibr" rid="B31">Hetz et&#xa0;al., 2002</xref>; <xref ref-type="bibr" rid="B42">Lagos et&#xa0;al., 2009</xref>). Pediocin has been observed to trigger apoptosis through a mechanism that remains unidentified (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>). Proteins capable of entering CRC cells and inducing cell cycle arrest and apoptosis by aspyrins (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>). Phenazine, a nitrogen-containing metabolite, is produced by various bacterial strains, with notable secretion observed in numerous Pseudomonas aeruginosa strains. This compound includes phenazine 1-carboxylic acid and phenazine 1,6-dicarboxylic acid (PDC) (<xref ref-type="bibr" rid="B88">Wolf and Els&#xe4;sser-Beile, 2009</xref>). Crucially, it induces G1 cell-cycle arrest, consequently prompting apoptosis, while also negatively impacting CRC cell viability and hampering DNA synthesis (<xref ref-type="bibr" rid="B34">Iglewski and Kabat, 1975</xref>; <xref ref-type="bibr" rid="B88">Wolf and Els&#xe4;sser-Beile, 2009</xref>). Recall antigens delivered via Listeria might serve as a viable option for cancer immunotherapy beyond neoantigens (<xref ref-type="bibr" rid="B73">Selvanesan et&#xa0;al., 2022</xref>). Listeriolysin O (LLO), a poisonous compound produced by the anaerobic microorganism Listeria monocytogenes, possesses the ability to infiltrate the cytoplasm of antigen-presenting cells and rupture the phagosome membranes (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Microbiological therapy for colorectal cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1299977-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Toxins and peptides related to microbiological therapy.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-13-1299977-g003.tif"/>
</fig>
<p>Following that, non-ribosomal peptides are discussed, which constitute an alternative group of peptides produced by bacteria, fungi, and cyanobacteria. These peptides play a role in combatting CRC. Lucentamycins, Arenamides, Ohmyungsamycins, Mixirins, and Urukthapelstatin A possess the ability to engage with CRC cells, either through direct interactions or indirect mechanisms (<xref ref-type="bibr" rid="B70">Sacks et&#xa0;al., 2018</xref>). For instance, sarcosamides A and B have demonstrated their potential in inhibiting the pro-inflammatory NF-&#x3ba;B signaling pathway by effectively blocking TNF-induced activation, ultimately leading to a reduction in inflammation (<xref ref-type="bibr" rid="B10">Byun et&#xa0;al., 2020</xref>). Consequently, this decrease in inflammation hinders the production of NO and PGE2, effectively opposing the activities of CRC cells (<xref ref-type="bibr" rid="B10">Byun et&#xa0;al., 2020</xref>). Cyclic depsipeptides, specifically Ohmyungsamycin A and B, display a discerning ability to impede the proliferation of CRC cells (<xref ref-type="bibr" rid="B83">Um et&#xa0;al., 2013</xref>; <xref ref-type="bibr" rid="B10">Byun et&#xa0;al., 2020</xref>). Mixirin, derived from <italic>Bacillus marinus</italic>, is a cyclic thiopeptide that can exhibit cytotoxicity against the HCT-116 (human colon cancer cell line) (<xref ref-type="bibr" rid="B93">Yamamoto et&#xa0;al., 2015</xref>). Urukthapelstatin A is a cyclic sulfur peptide produced by <italic>Mechercharimyces asporophorigenens</italic>, a marine microorganism affiliated with the <italic>Thermoactinobacteriaceae</italic> family (<xref ref-type="bibr" rid="B55">Matsuo et&#xa0;al., 2007</xref>). This compound exerts inhibitory effects on the proliferation of HCT-116 cell line through its biological activity (<xref ref-type="bibr" rid="B61">Mueller et&#xa0;al., 2022</xref>).</p>
</sec>
<sec id="s7" sec-type="conclusions">
<label>7</label>
<title>Conclusion</title>
<p>Intestinal microorganisms constitute a rich ecosystem, with more than 1000 species of bacteria belonging to 50 genera and 17 families. Their composition depends largely on environmental conditions, and there are differences among individuals. With the in-depth study of intestinal bacteria, we can find that intestinal bacteria and their metabolites have many effects on CRC, such as inflammatory transformation, malignant transformation of intestinal polyps, tumor escape, treatment and so on. According to relevant studies, it can be reported that apoptosis of CRC cells can be induced by inhibiting the activity of glutamate dehydrogenase, regulating the MAPK signaling pathway, PI3K/AKT, and other related pathway mechanisms, which are crucial for the development of CRC (<xref ref-type="bibr" rid="B12">Chang and Kang, 2023</xref>; <xref ref-type="bibr" rid="B96">Yang et&#xa0;al., 2023</xref>).</p>
<p>In this paper, we reviewed that intestinal bacteria can participate in adenoma-adenocarcinoma transformation through their metabolites and affect the DNA coding of intestinal cells. It is believed that in the initial stage of CRC, &#x201c;driver&#x201d; bacteria are dominant in the intestine, which leads to adenoma and even malignant tumor with the increase of DNA damage and chromosome instability in intestinal cells. In addition, intestinal flora can directly induce tumor-associated immune cell infiltration and promote the formation of tumor microenvironment. In some familial hereditary adenomatous polyposis, specific intestinal bacteria often play a role in promoting the carcinogenesis of adenomas. No matter which kind of colon cancer patients, the determination of intestinal flora and its metabolites has great clinical significance, because it may early warn the occurrence of colorectal cancer and adenoma, or improve the prognosis of patients with CRC. Tailoring the regulation of gut microbiota on an individual basis is poised to emerge as a focal point and innovative strategy in the realm of preventing and supporting the treatment of CRC.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>JH: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. BZ: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YZ: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. TY: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YC: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. JL: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. YY: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. HS: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. DS: Conceptualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abed</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Emg&#xe5;rd</surname> <given-names>J. E. M.</given-names>
</name>
<name>
<surname>Zamir</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Faroja</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Almogy</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Grenov</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2016</year>). <article-title>Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed gal-galNAc</article-title>. <source>Cell Host Microbe</source> <volume>20</volume> (<issue>2</issue>), <fpage>215</fpage>&#x2013;<lpage>225</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2016.07.006</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agrawal</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Acharya</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Adholeya</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Barrow</surname> <given-names>C. J.</given-names>
</name>
<name>
<surname>Deshmukh</surname> <given-names>S. K.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Nonribosomal peptides from marine microbes and their antimicrobial and anticancer potential</article-title>. <source>Front. Pharmacol.</source> <volume>8</volume>, <elocation-id>828</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2017.00828</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmadi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ghollasi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Hosseini</surname> <given-names>H. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The apoptotic impact of nisin as a potent bacteriocin on the colon cancer cells</article-title>. <source>Microb. Pathog.</source> <volume>111</volume>, <fpage>193</fpage>&#x2013;<lpage>197</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.micpath.2017.08.037</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname> <given-names>J. L.</given-names>
</name>
<name>
<surname>Posma</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Poynter</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Mason</surname> <given-names>S. E.</given-names>
</name>
<name>
<surname>Doria</surname> <given-names>M. L.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer</article-title>. <source>Microbiome</source> <volume>11</volume> (<issue>1</issue>), <fpage>100</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40168-023-01518-w</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alon-Maimon</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Mandelboim</surname> <given-names>O.</given-names>
</name>
<name>
<surname>Bachrach</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Fusobacterium nucleatum and cancer</article-title>. <source>Periodontol 2000</source> <volume>89</volume> (<issue>1</issue>), <fpage>166</fpage>&#x2013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1111/prd.12426</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Aptsiauri</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Ruiz-Cabello</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Garrido</surname> <given-names>F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy</article-title>. <source>Cell Mol. Immunol.</source> <volume>18</volume> (<issue>3</issue>), <fpage>556</fpage>&#x2013;<lpage>565</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41423-021-00634-7</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Avril</surname> <given-names>M.</given-names>
</name>
<name>
<surname>DePaolo</surname> <given-names>R. W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>&#x201c;Driver-passenger&#x201d; bacteria and their metabolites in the pathogenesis of colorectal cancer</article-title>. <source>Gut Microbes</source> <volume>13</volume> (<issue>1</issue>), <fpage>1941710</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2021.1941710</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azadi</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Golchini</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Delazar</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Abarghooi Kahaki</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Dehnavi</surname> <given-names>S. M.</given-names>
</name>
<name>
<surname>Payandeh</surname> <given-names>Z.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines</article-title>. <source>Biol. Proced Online</source> <volume>23</volume> (<issue>1</issue>), <fpage>13</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12575-021-00147-7</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biarc</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>I. S.</given-names>
</name>
<name>
<surname>Pini</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Goss&#xe9;</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Richert</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Thiers&#xe9;</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2004</year>). <article-title>Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S.bovis)</article-title>. <source>Carcinogenesis</source> <volume>25</volume> (<issue>8</issue>), <fpage>1477</fpage>&#x2013;<lpage>1484</lpage>. doi: <pub-id pub-id-type="doi">10.1093/carcin/bgh091</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byun</surname> <given-names>W. S.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>Y. H.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>W. K.</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>D. C.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>S. K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antitumor activity of ohmyungsamycin A through the regulation of the Skp2-p27 axis and MCM4 in human colorectal cancer cells</article-title>. <source>J. Nat. Prod</source> <volume>83</volume> (<issue>1</issue>), <fpage>118</fpage>&#x2013;<lpage>126</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jnatprod.9b00918</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Center</surname> <given-names>M. M.</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>R. A.</given-names>
</name>
<name>
<surname>Ward</surname> <given-names>E.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Worldwide variations in colorectal cancer</article-title>. <source>CA: Cancer J. Clin.</source> <volume>59</volume> (<issue>6</issue>), <fpage>366</fpage>&#x2013;<lpage>378</lpage>. doi: <pub-id pub-id-type="doi">10.3322/caac.20038</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname> <given-names>S. N.</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>S. C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Decursinol angelate inhibits glutamate dehydrogenase 1 activity and induces intrinsic apoptosis in MDR-CRC cells</article-title>. <source>Cancers (Basel)</source> <volume>15</volume> (<issue>14</issue>), <fpage>3541</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers15143541</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chat</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Dalmasso</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Godfraind</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Bonnin</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Beyrouthy</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Bonnet</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Cytotoxic necrotizing factor 1 hinders colon tumorigenesis induced by colibactin-producing Escherichia coli in ApcMin/+ mice</article-title>. <source>Gut Microbes</source> <volume>15</volume> (<issue>1</issue>), <fpage>2229569</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2023.2229569</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Bifidobacterium adolescentis orchestrates CD143+ cancer-associated fibroblasts to suppress colorectal tumorigenesis by Wnt signaling-regulated GAS1</article-title>. <source>Cancer Commun. (Lond)</source>. <volume>43</volume> (<issue>9</issue>), <fpage>1027</fpage>&#x2013;<lpage>1047</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cac2.12469</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clavenna</surname> <given-names>M. G.</given-names>
</name>
<name>
<surname>La Vecchia</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sculco</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Joseph</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Barberis</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Amede</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Distinct signatures of tumor-associated microbiota and metabolome in low-grade vs. High-grade dysplastic colon polyps: inference of their role in tumor initiation and progression</article-title>. <source>Cancers (Basel)</source> <volume>15</volume> (<issue>12</issue>), <fpage>3065</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers15123065</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Rousseau</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Vidal</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Colle</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Diaz</surname> <given-names>L. A.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Andr&#xe9;</surname> <given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond</article-title>. <source>Target Oncol.</source> <volume>15</volume> (<issue>1</issue>), <fpage>11</fpage>&#x2013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11523-019-00690-0</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejea</surname> <given-names>C. M.</given-names>
</name>
<name>
<surname>Fathi</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Craig</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Boleij</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Taddese</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Geis</surname> <given-names>A. L.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria</article-title>. <source>Science</source> <volume>359</volume> (<issue>6375</issue>), <fpage>592</fpage>&#x2013;<lpage>597</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aah3648</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodd</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Spitzer</surname> <given-names>M. H.</given-names>
</name>
<name>
<surname>Van Treuren</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Merrill</surname> <given-names>B. D.</given-names>
</name>
<name>
<surname>Hryckowian</surname> <given-names>A. J.</given-names>
</name>
<name>
<surname>Higginbottom</surname> <given-names>S. K.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites</article-title>. <source>Nature</source> <volume>551</volume> (<issue>7682</issue>), <fpage>648</fpage>&#x2013;<lpage>652</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature24661</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dougherty</surname> <given-names>M. W.</given-names>
</name>
<name>
<surname>Vald&#xe9;s-Mas</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Wernke</surname> <given-names>K. M.</given-names>
</name>
<name>
<surname>Gharaibeh</surname> <given-names>R. Z.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Brant</surname> <given-names>J. O.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors</article-title>. <source>Neoplasia</source> <volume>43</volume>, <fpage>100918</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neo.2023.100918</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyson</surname> <given-names>J. K.</given-names>
</name>
<name>
<surname>Rutter</surname> <given-names>M. D.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk</article-title>? <source>World J. Gastroenterol.</source> <volume>18</volume> (<issue>29</issue>), <fpage>3839</fpage>&#x2013;<lpage>3848</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v18.i29.3839</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eslami</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Sadrifar</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Karbalaei</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Keikha</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kobyliak</surname> <given-names>N. M.</given-names>
</name>
<name>
<surname>Yousefi</surname> <given-names>B.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Importance of the microbiota inhibitory mechanism on the warburg effect in colorectal cancer cells</article-title>. <source>J. Gastrointest Cancer</source> <volume>51</volume> (<issue>3</issue>), <fpage>738</fpage>&#x2013;<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12029-019-00329-3</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Evans</surname> <given-names>M. D.</given-names>
</name>
<name>
<surname>Dizdaroglu</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Cooke</surname> <given-names>M. S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Oxidative DNA damage and disease: induction, repair and significance</article-title>. <source>Mutat. Res.</source> <volume>567</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mrrev.2003.11.001</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname> <given-names>M. E.</given-names>
</name>
<name>
<surname>Lemmon</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Mauchline</surname> <given-names>M. L.</given-names>
</name>
<name>
<surname>Davis</surname> <given-names>T. O.</given-names>
</name>
<name>
<surname>Giaccia</surname> <given-names>A. J.</given-names>
</name>
<name>
<surname>Minton</surname> <given-names>N. P.</given-names>
</name>
<etal/>
</person-group>. (<year>1996</year>). <article-title>Anaerobic bacteria as a delivery system for cancer gene therapy: in <italic>vitro</italic> activation of 5-fluorocytosine by genetically engineered clostridia</article-title>. <source>Gene Ther.</source> <volume>3</volume> (<issue>2</issue>), <fpage>173</fpage>&#x2013;<lpage>178</lpage>.</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Bi</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer</article-title>. <source>Signal Transduct Target Ther.</source> <volume>6</volume> (<issue>1</issue>), <fpage>398</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-021-00795-x</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y. X.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer</article-title>. <source>Neoplasia</source> <volume>35</volume>, <fpage>100850</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neo.2022.100850</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Serrano</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Mukhedkar</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Hultin</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Rudsander</surname> <given-names>U.</given-names>
</name>
<name>
<surname>Wettergren</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Ure</surname> <given-names>A. E.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Assessment of bacterial and viral gut communities in healthy and tumoral colorectal tissue using RNA and DNA deep sequencing</article-title>. <source>Cancer Med</source>. <volume>12</volume> (<issue>18</issue>), <fpage>19291</fpage>&#x2013;<lpage>19300</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cam4.6483</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geng</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>H.</given-names>
</name>
<etal/>
</person-group>. (<year>2014</year>). <article-title>Co-occurrence of driver and passenger bacteria in human colorectal cancer</article-title>. <source>Gut Pathog.</source> <volume>6</volume>, <fpage>26</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1757-4749-6-26</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grivennikov</surname> <given-names>S. I.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Mucida</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Stewart</surname> <given-names>C. A.</given-names>
</name>
<name>
<surname>Schnabl</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Jauch</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2012</year>). <article-title>Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth</article-title>. <source>Nature</source> <volume>491</volume> (<issue>7423</issue>), <fpage>254</fpage>&#x2013;<lpage>258</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature114&#x200b;&#x200b;65</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hale</surname> <given-names>V. L.</given-names>
</name>
<name>
<surname>Jeraldo</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Mundy</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Priya</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers</article-title>. <source>Genome Med.</source> <volume>10</volume> (<issue>1</issue>), <fpage>78</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13073-018-0586-6</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harnack</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Berger</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Mollenkopf</surname> <given-names>H.-J.</given-names>
</name>
<name>
<surname>Strowig</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Sigal</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Short-term mucosal disruption enables colibactin-producing E. coli to cause long-term perturbation of colonic homeostasis</article-title>. <source>Gut Microbes</source> <volume>15</volume> (<issue>1</issue>), <fpage>2233689</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/19490976.2023.2233689</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hetz</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Bono</surname> <given-names>M. R.</given-names>
</name>
<name>
<surname>Barros</surname> <given-names>L. F.</given-names>
</name>
<name>
<surname>Lagos</surname> <given-names>R.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>99</volume> (<issue>5</issue>), <fpage>2696</fpage>&#x2013;<lpage>2701</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.052709699</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hezaveh</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Shinde</surname> <given-names>R. S.</given-names>
</name>
<name>
<surname>Kl&#xf6;tgen</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Halaby</surname> <given-names>M. J.</given-names>
</name>
<name>
<surname>Lamorte</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Ciudad</surname> <given-names>M. T.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity</article-title>. <source>Immunity</source> <volume>55</volume> (<issue>2</issue>), <fpage>324</fpage>&#x2013;<lpage>340.e8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2022.01.006</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsueh</surname> <given-names>C.-Y.</given-names>
</name>
<name>
<surname>Lau</surname> <given-names>H.-C.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck</article-title>. <source>Cancer</source> <volume>128</volume> (<issue>17</issue>), <fpage>3170</fpage>&#x2013;<lpage>3184</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.34338</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iglewski</surname> <given-names>B. H.</given-names>
</name>
<name>
<surname>Kabat</surname> <given-names>D.</given-names>
</name>
</person-group> (<year>1975</year>). <article-title>NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>72</volume> (<issue>6</issue>), <fpage>2284</fpage>&#x2013;<lpage>2288</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.72.6.2284</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jans</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kolata</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Blancke</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Ciers</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Dohlman</surname> <given-names>A. B.</given-names>
</name>
<name>
<surname>Kusakabe</surname> <given-names>T.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Colibactin-induced genotoxicity and colorectal cancer exacerbation critically depends on adhesin-mediated epithelial binding</article-title>. <source>bioRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2023.08.16.553526</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasper</surname> <given-names>S. H.</given-names>
</name>
<name>
<surname>Morell-Perez</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Wyche</surname> <given-names>T. P.</given-names>
</name>
<name>
<surname>Sana</surname> <given-names>T. R.</given-names>
</name>
<name>
<surname>Lieberman</surname> <given-names>L. A.</given-names>
</name>
<name>
<surname>Hett</surname> <given-names>E. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>5321</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-020-62139-z</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knudsen</surname> <given-names>M. D.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Polychronidis</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Berstad</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Development and validation of a risk prediction model for post-polypectomy colorectal cancer in the USA: a prospective cohort study</article-title>. <source>EClinicalMedicine</source> <volume>62</volume>, <fpage>102139</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102139</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohoutova</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Forstlova</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Moravkova</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Cyrany</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Bosak</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Smajs</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Bacteriocin production by mucosal bacteria in current and previous colorectal neoplasia</article-title>. <source>BMC Cancer</source> <volume>20</volume> (<issue>1</issue>), <fpage>39</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-020-6512-5</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>You</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Fusobacterium nucleatum-triggered neutrophil extracellular traps facilitate colorectal carcinoma progression</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>42</volume> (<issue>1</issue>), <fpage>236</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-023-02817-8</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korsten</surname> <given-names>S. G. P. J.</given-names>
</name>
<name>
<surname>Vromans</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Garssen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Willemsen</surname> <given-names>L. E. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Butyrate protects barrier integrity and suppresses immune activation in a caco-2/PBMC co-culture model while HDAC inhibition mimics butyrate in restoring cytokine-induced barrier disruption</article-title>. <source>Nutrients</source> <volume>15</volume> (<issue>12</issue>), <fpage>2760</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu15122760</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostic</surname> <given-names>A. D.</given-names>
</name>
<name>
<surname>Chun</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Robertson</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Glickman</surname> <given-names>J. N.</given-names>
</name>
<name>
<surname>Gallini</surname> <given-names>C. A.</given-names>
</name>
<name>
<surname>Michaud</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment</article-title>. <source>Cell Host Microbe</source> <volume>14</volume> (<issue>2</issue>), <fpage>207</fpage>&#x2013;<lpage>215</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2013.07.007</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagos</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Tello</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Mercado</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Garc&#xed;a</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Monasterio</surname> <given-names>O.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin</article-title>. <source>Curr. Pharm. Biotechnol.</source> <volume>10</volume> (<issue>1</issue>), <fpage>74</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.2174/138920109787048643</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavelle</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Sokol</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Gut microbiota-derived metabolites as key actors in inflammatory bowel disease</article-title>. <source>Nat. Rev. Gastroenterol. Hepatol.</source> <volume>17</volume> (<issue>4</issue>), <fpage>223</fpage>&#x2013;<lpage>237</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-019-0258-z</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname> <given-names>H. K. M.</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>E. K. K.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Felicianna</surname>
</name>
<name>
<surname>Ismaiah</surname> <given-names>M. J.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Zearalenone attenuates colitis associated colorectal tumorigenesis through Ras/Raf/ERK pathway suppression and SCFA-producing bacteria promotion</article-title>. <source>BioMed. Pharmacother.</source> <volume>164</volume>, <fpage>114973</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114973</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W.-X.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C.-A.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Carnobacterium Maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice</article-title>. <source>Cancer Cell</source> <volume>41</volume> (<issue>8</issue>), <fpage>1450</fpage>&#x2013;<lpage>1465.e8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ccell.2023.06.011</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Features of combined gut bacteria and fungi from a Chinese cohort of colorectal cancer, colorectal adenoma, and post-operative patients</article-title>. <source>Front. Microbiol.</source> <volume>14</volume>, <elocation-id>1236583</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2023.1236583</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Du</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers</article-title>. <source>J. Immunother. Cancer</source> <volume>11</volume> (<issue>8</issue>), <elocation-id>e007420</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/jitc-2023-007420</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Ouyang</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The regulatory network of microRNA in the metabolism of colorectal cancer</article-title>. <source>J. Cancer</source> <volume>12</volume> (<issue>24</issue>), <fpage>7454</fpage>&#x2013;<lpage>7464</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.61618</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>42</volume> (<issue>1</issue>), <fpage>172</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-023-02746-6</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l-Serine-Mediated NK Cell Activation</article-title>. <source>Res. (Wash D C)</source> <volume>6</volume>, <fpage>0127</fpage>. doi: <pub-id pub-id-type="doi">10.34133/research.0127</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway</article-title>. <source>Cell Death Differ</source> <volume>27</volume> (<issue>6</issue>), <fpage>1765</fpage>&#x2013;<lpage>1781</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41418-019-0460-0</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Lau</surname> <given-names>H. C.-H.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis</article-title>. <source>Gastroenterology</source> <volume>160</volume> (<issue>7</issue>), <fpage>2395</fpage>&#x2013;<lpage>2408</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2021.02.020</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Dun</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Long non-coding RNA EVADR induced by Fusobacterium nucleatum infection promotes colorectal cancer metastasis</article-title>. <source>Cell Rep.</source> <volume>40</volume> (<issue>3</issue>), <fpage>111127</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2022.111127</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martarelli</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Pompei</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Mazzoni</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197</article-title>. <source>Chemotherapy</source> <volume>55</volume> (<issue>6</issue>), <fpage>425</fpage>&#x2013;<lpage>432</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000264689</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuo</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Kanoh</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Imagawa</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Adachi</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Nishizawa</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Shizuri</surname> <given-names>Y.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. II. Physico-chemical properties and structural elucidation</article-title>. <source>J. Antibiot (Tokyo)</source> <volume>60</volume> (<issue>4</issue>), <fpage>256</fpage>&#x2013;<lpage>260</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ja.2007.30</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Mehrazarin</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Tangwanichgapong</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Fusobacterium nucleatum secretes amyloid-like FadA to enhance pathogenicity</article-title>. <source>EMBO Rep.</source> <volume>22</volume> (<issue>7</issue>), <fpage>e52891</fpage>. doi: <pub-id pub-id-type="doi">10.15252/embr.202152891</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mengesha</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Dubois</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Chiu</surname> <given-names>R. K.</given-names>
</name>
<name>
<surname>Paesmans</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wouters</surname> <given-names>B. G.</given-names>
</name>
<name>
<surname>Lambin</surname> <given-names>P.</given-names>
</name>
<etal/>
</person-group>. (<year>2007</year>). <article-title>Potential and limitations of bacterial-mediated cancer therapy</article-title>. <source>Front. Biosci.</source> <volume>12</volume>, <fpage>3880</fpage>&#x2013;<lpage>3891</lpage>. doi: <pub-id pub-id-type="doi">10.2741/2357</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mima</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Sukawa</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Nishihara</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>Z. R.</given-names>
</name>
<name>
<surname>Yamauchi</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Inamura</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Fusobacterium nucleatum and T cells in colorectal carcinoma</article-title>. <source>JAMA Oncol.</source> <volume>1</volume> (<issue>5</issue>), <fpage>653</fpage>&#x2013;<lpage>661</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2015.1377</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montalban-Arques</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Scharl</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy</article-title>. <source>EBioMedicine</source> <volume>48</volume>, <fpage>648</fpage>&#x2013;<lpage>655</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2019.09.050</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mouradov</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Greenfield</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S.</given-names>
</name>
<name>
<surname>In</surname> <given-names>E.-J.</given-names>
</name>
<name>
<surname>Storey</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Sakthianandeswaren</surname> <given-names>A.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Oncomicrobial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer</article-title>. <source>Gastroenterology</source> <volume>165</volume> (<issue>1</issue>), <fpage>104</fpage>&#x2013;<lpage>120</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2023.03.205</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname> <given-names>A. L.</given-names>
</name>
<name>
<surname>Brockmueller</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Fahimi</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Ghotbi</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Hashemi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Sadri</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Bacteria-mediated modulatory strategies for colorectal cancer treatment</article-title>. <source>Biomedicines</source> <volume>10</volume> (<issue>4</issue>), <fpage>832</fpage>. doi: <pub-id pub-id-type="doi">10.3390/biomedicines10040832</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nawab</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Bao</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>L.-H.</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>The pathogenicity of fusobacterium nucleatum modulated by dietary fibers-A possible missing link between the dietary composition and the risk of colorectal cancer</article-title>. <source>Microorganisms</source> <volume>11</volume> (<issue>8</issue>), <fpage>2004</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms11082004</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname> <given-names>V. H.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H. S.</given-names>
</name>
<name>
<surname>Ha</surname> <given-names>J. M.</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Choy</surname> <given-names>H. E.</given-names>
</name>
<name>
<surname>Min</surname> <given-names>J. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer</article-title>. <source>Cancer Res.</source> <volume>70</volume> (<issue>1</issue>), <fpage>18</fpage>&#x2013;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3453</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Connell</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Bennett</surname> <given-names>M. W.</given-names>
</name>
<name>
<surname>Nally</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Houston</surname> <given-names>A.</given-names>
</name>
<name>
<surname>O&#x2019;Sullivan</surname> <given-names>G. C.</given-names>
</name>
<name>
<surname>Shanahan</surname> <given-names>F.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict</article-title>. <source>Ann. N Y Acad. Sci.</source> <volume>910</volume>, <fpage>178</fpage>&#x2013;<lpage>92</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06708.x</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pahle</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Menzel</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Niesler</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Kobelt</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Aumann</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Rivera</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Rapid eradication of colon carcinoma by Clostridium perfringens Enterotoxin suicidal gene therapy</article-title>. <source>BMC Cancer</source> <volume>17</volume> (<issue>1</issue>), <fpage>129</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-017-3123-x</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perez-Lopez</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Behnsen</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Nuccio</surname> <given-names>S. P.</given-names>
</name>
<name>
<surname>Raffatellu</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Mucosal immunity to pathogenic intestinal bacteria</article-title>. <source>Nat. Rev. Immunol.</source> <volume>16</volume> (<issue>3</issue>), <fpage>135</fpage>&#x2013;<lpage>148</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri.2015.17</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puccetti</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Fallarino</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Italiano</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Soubeyran</surname> <given-names>I.</given-names>
</name>
<name>
<surname>MacGrogan</surname> <given-names>G.</given-names>
</name>
<name>
<surname>Debled</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2015</year>). <article-title>Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers</article-title>. <source>PloS One</source> <volume>10</volume> (<issue>4</issue>), <elocation-id>e0122046</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0122046</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rebersek</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Gut microbiome and its role in colorectal cancer</article-title>. <source>BMC Cancer</source> <volume>21</volume> (<issue>1</issue>), <fpage>1325</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-021-09054-2</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Routy</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Gopalakrishnan</surname> <given-names>V.</given-names>
</name>
<name>
<surname>Daill&#xe8;re</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Wargo</surname> <given-names>J. A.</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The gut microbiota influences anticancer immunosurveillance and general health</article-title>. <source>Nat. Rev. Clin. Oncol.</source> <volume>15</volume> (<issue>6</issue>), <fpage>382</fpage>&#x2013;<lpage>396</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41571-018-0006-2</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacks</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Baxter</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>B. C. V.</given-names>
</name>
<name>
<surname>Carpenter</surname> <given-names>J. S.</given-names>
</name>
<name>
<surname>Cognard</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Dippel</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2018</year>). <article-title>Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke</article-title>. <source>Int. J. stroke: Off. J. Int. Stroke Soc.</source> <volume>13</volume> (<issue>6</issue>), <fpage>612</fpage>&#x2013;<lpage>632</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jvir.2017.11.026</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Mori</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Kishi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Fujiwara-Tani</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Ohmori</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Nishiguchi</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>Effect of proton pump inhibitors on colorectal cancer</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume> (<issue>11</issue>), <fpage>3877</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21113877</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sears</surname> <given-names>C. L.</given-names>
</name>
<name>
<surname>Pardoll</surname> <given-names>D. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Perspective: alpha-bugs, their microbial partners, and the link to colon cancer</article-title>. <source>J. Infect. Dis.</source> <volume>203</volume> (<issue>3</issue>), <fpage>306</fpage>&#x2013;<lpage>311</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jinfdis/jiq061</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selvanesan</surname> <given-names>B. C.</given-names>
</name>
<name>
<surname>Chandra</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Quispe-Tintaya</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Jahangir</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Patel</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Meena</surname> <given-names>K.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice</article-title>. <source>Sci. Transl. Med.</source> <volume>14</volume> (<issue>637</issue>), <elocation-id>eabc1600</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scitranslmed.abc1600</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Emerging roles of the gut microbiota in cancer immunotherapy</article-title>. <source>Front. Immunol.</source> <volume>14</volume>, <elocation-id>1139821</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2023.1139821</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Simnica</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Schulthei&#xdf;</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Scholz</surname> <given-names>R.</given-names>
</name>
<name>
<surname>Tintelnot</surname> <given-names>J.</given-names>
</name>
<name>
<surname>G&#xf6;kkurt</surname> <given-names>E.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer</article-title>. <source>J. Immunother. Cancer</source> <volume>9</volume> (<issue>7</issue>), <elocation-id>e002844</elocation-id>. doi: <pub-id pub-id-type="doi">10.1136/jitc-2021-002844</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sui</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M.</given-names>
</name>
<etal/>
</person-group>. (<year>2020</year>). <article-title>The relationship between KRAS gene mutation and intestinal flora in tumor tissues of colorectal cancer patients</article-title>. <source>Ann. Transl. Med.</source> <volume>8</volume> (<issue>17</issue>), <fpage>1085</fpage>. doi: <pub-id pub-id-type="doi">10.21037/atm-20-5622</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sulit</surname> <given-names>A. K.</given-names>
</name>
<name>
<surname>Daigneault</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Allen-Vercoe</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Silander</surname> <given-names>O. K.</given-names>
</name>
<name>
<surname>Hock</surname> <given-names>B.</given-names>
</name>
<name>
<surname>McKenzie</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment</article-title>. <source>NPJ Biofilms Microbiomes</source> <volume>9</volume> (<issue>1</issue>), <fpage>59</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41522-023-00429-w</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>G.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Potential effects of gut microbiota on host cancers: focus on immunity, DNA damage, cellular pathways, and anticancer therapy</article-title>. <source>ISME J.</source> <volume>17</volume> (<issue>10</issue>), <fpage>1535</fpage>&#x2013;<lpage>1551</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41396-023-01483-0</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ternes</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Tsenkova</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Pozdeev</surname> <given-names>V. I.</given-names>
</name>
<name>
<surname>Meyers</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Koncina</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Atatri</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>The gut microbial metabolite formate exacerbates colorectal cancer progression</article-title>. <source>Nat. Metab.</source> <volume>4</volume> (<issue>4</issue>), <fpage>458</fpage>&#x2013;<lpage>475</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s42255-022-00558-0</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Cramer</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Rhoades</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Estep</surname> <given-names>K. N.</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>APC and P53 mutations synergise to create a therapeutic vulnerability to NOTUM inhibition in advanced colorectal cancer</article-title>. <source>Gut</source>. <volume>72</volume> (<issue>12</issue>), <fpage>2294</fpage>&#x2013;<lpage>2306</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2022-329140</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tjalsma</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Boleij</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Marchesi</surname> <given-names>J. R.</given-names>
</name>
<name>
<surname>Dutilh</surname> <given-names>B. E.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>10</volume> (<issue>8</issue>), <fpage>575</fpage>&#x2013;<lpage>582</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro2819</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomii</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Higa</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Naito</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kurata</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Kobayashi</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Takei</surname> <given-names>C.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Activation of the TLR4-JNK but not the TLR4-ERK pathway induced by indole-3-acetic acid exerts anti-proliferative effects on Caco-2 cells</article-title>. <source>Biosci. Biotechnol. Biochem.</source> <volume>87</volume> (<issue>8</issue>), <fpage>839</fpage>&#x2013;<lpage>849</lpage>. doi: <pub-id pub-id-type="doi">10.1093/bbb/zbad055</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Um</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>T. J.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>B. Y.</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S.-H.</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>S. K.</given-names>
</name>
<etal/>
</person-group>. (<year>2013</year>). <article-title>Ohmyungsamycins A and B: cytotoxic and antimicrobial cyclic peptides produced by Streptomyces sp</article-title>. <source>volcanic island. J. Org Chem.</source> <volume>78</volume> (<issue>24</issue>), <fpage>12321</fpage>&#x2013;<lpage>12329</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/jo401974g</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vallera</surname> <given-names>D. A.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>N.</given-names>
</name>
<name>
<surname>Panoskaltsis-Mortari</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>W. A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT</article-title>. <source>J. Natl. Cancer Inst</source> <volume>94</volume> (<issue>8</issue>), <fpage>597</fpage>&#x2013;<lpage>606</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jnci/94.8.597</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Destroying pathogen-tumor symbionts synergizing with catalytic therapy of colorectal cancer by biomimetic protein-supported single-atom nanozyme</article-title>. <source>Signal Transduction Targeted Ther.</source> <volume>8</volume> (<issue>1</issue>), <fpage>277</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41392-023-01491-8</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Tu</surname> <given-names>Y.-X.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>X.-L.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>S.-Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Male-biased gut microbiome and metabolites aggravate colorectal cancer development</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>10</volume> (<issue>25</issue>), <elocation-id>e2206238</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/advs.202206238</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Role of tumor microenvironment in tumorigenesis</article-title>. <source>J. Cancer</source> <volume>8</volume> (<issue>5</issue>), <fpage>761</fpage>&#x2013;<lpage>773</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.17648</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Els&#xe4;sser-Beile</surname> <given-names>U.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Pseudomonas exotoxin A: from virulence factor to anti-cancer agent</article-title>. <source>Int. J. Med. Microbiol.</source> <volume>299</volume> (<issue>3</issue>), <fpage>161</fpage>&#x2013;<lpage>176</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijmm.2008.08.003</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Lewis</surname> <given-names>A.</given-names>
</name>
<name>
<surname>Beaugerie</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Svrcek</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Kirchgesner</surname> <given-names>J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps</article-title>. <source>Aliment Pharmacol. Ther.</source> <volume>57</volume> (<issue>12</issue>), <fpage>1445</fpage>&#x2013;<lpage>1452</lpage>. doi: <pub-id pub-id-type="doi">10.1111/apt.17495</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Impacts of microRNAs induced by the gut microbiome on regulating the development of colorectal cancer</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>12</volume>, <elocation-id>804689</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2022.804689</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2021</year>). <article-title>Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization</article-title>. <source>Gut Microbes</source> <volume>13</volume> (<issue>1</issue>), <fpage>1980347</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2021.1980347</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Mi</surname> <given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Q.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Biglycan regulated colorectal cancer progress by modulating enteric neuron-derived IL-10 and abundance of Bacteroides thetaiotaomicron</article-title>. <source>iScience</source> <volume>26</volume> (<issue>9</issue>), <fpage>107515</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.isci.2023.107515</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Shiraishi</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Are cyclic lipopeptides produced by Bacillus amyloliquefaciens S13-3 responsible for the plant defence response in strawberry against Colletotrichum gloeosporioides</article-title>? <source>Lett. Appl. Microbiol.</source> <volume>60</volume> (<issue>4</issue>), <fpage>379</fpage>&#x2013;<lpage>386</lpage>. doi: <pub-id pub-id-type="doi">10.1111/lam.12382</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>W.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>ENPP2 inhibitor improves proliferation in AOM/DSS-induced colorectal cancer mice via remodeling the gut barrier function and gut microbiota composition</article-title>. <source>Pharmacol. Res.</source> <volume>195</volume>, <fpage>106877</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2023.106877</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Tong</surname> <given-names>B.</given-names>
</name>
<etal/>
</person-group>. (<year>2024</year>). <article-title>Vitamin A deficiency suppresses CEACAM1 to impair colonic epithelial barrier function via downregulating microbial-derived short-chain fatty acids</article-title>. <source>Genes Dis.</source> <volume>11</volume> (<issue>2</issue>), <fpage>1066</fpage>&#x2013;<lpage>1081</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.gendis.2023.03.032</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Sertaconazole nitrate targets IDO1 and regulates the MAPK signaling pathway to induce autophagy and apoptosis in CRC cells</article-title>. <source>Eur. J. Pharmacol.</source> <volume>942</volume>, <fpage>175515</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175515</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Su</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Fusobacterium nucleatum promotes liver metastasis in colorectal cancer by regulating the hepatic immune niche and altering gut microbiota</article-title>. <source>Aging (Albany NY)</source> <volume>14</volume> (<issue>4</issue>), <fpage>1941</fpage>&#x2013;<lpage>1958</lpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.203914</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>L. C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis</article-title>. <source>J. BioMed. Sci.</source> <volume>25</volume> (<issue>1</issue>), <fpage>79</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12929-018-0483-8</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>Y.-N.</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>J.-Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Gut microbiota and colorectal cancer</article-title>. <source>Gastrointest Tumors</source> <volume>2</volume> (<issue>1</issue>), <fpage>26</fpage>&#x2013;<lpage>32</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000380892</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>T.</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>D.</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J.</given-names>
</name>
<etal/>
</person-group>. (<year>2017</year>). <article-title>Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy</article-title>. <source>Cell</source> <volume>170</volume> (<issue>3</issue>), <fpage>548</fpage>&#x2013;<lpage>563.e516</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2017.07.008</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>B.</given-names>
</name>
<name>
<surname>Song</surname> <given-names>B.</given-names>
</name>
<etal/>
</person-group>. (<year>2023</year>). <article-title>Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients</article-title>. <source>Front. Pharmacol.</source> <volume>14</volume>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2023.1244752</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L.</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>S.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C.</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>D.</given-names>
</name>
<etal/>
</person-group>. (<year>2022</year>). <article-title>Fusobacterium nucleatum promotes colorectal cancer cells adhesion to endothelial cells and facilitates extravasation and metastasis by inducing ALPK1/NF-&#x3ba;B/ICAM1 axis</article-title>. <source>Gut Microbes</source> <volume>14</volume> (<issue>1</issue>), <fpage>2038852</fpage>. doi: <pub-id pub-id-type="doi">10.1080/19490976.2022.2038852</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>M.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X. M.</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>P.</given-names>
</name>
<name>
<surname>Baranov</surname> <given-names>E.</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source> <volume>102</volume> (<issue>3</issue>), <fpage>755</fpage>&#x2013;<lpage>760</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.0408422102</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname> <given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J. Y.</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H. W.</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C. M.</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>A. Z.</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>Y.</given-names>
</name>
<etal/>
</person-group>. (<year>2005</year>). <article-title>Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system</article-title>. <source>World J. Gastroenterol.</source> <volume>11</volume> (<issue>39</issue>), <fpage>6125</fpage>&#x2013;<lpage>6129</lpage>. doi: <pub-id pub-id-type="doi">10.3748/wjg.v11.i39.6125</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>